AlgoSource

About AlgoSource

AlgoSource specializes in developing and commercializing nutraceuticals derived from microalgae and other marine ingredients, such as marine magnesium and collagen. These products are designed for nutraceutical and preventive health applications.

Vision and Mission
Since its inception in 2012, AlgoSource has been guided by the vision “Microalgae for Health.” The company has developed innovative microalgae-based products, rigorously evaluated through placebo-controlled clinical studies to ensure efficacy. AlgoSource’s integrated research and development approach encompasses the entire microalgae value chain: cultivation, biorefining, and the production of stabilized liquid extracts.

Market Presence
AlgoSource markets its bioactive extracts in the B2B sector, serving nutraceutical professionals. It offers dietary supplements under its own brand or as a contract manufacturer. The company exports 50% of its products, mainly to Europe and Asia.

Supportive Care Initiative
Beyond its consumer-focused supplements, AlgoSource is advancing a supportive care activity aimed at enhancing patients’ quality of life. These products are positioned as dietary supplements to assist patients during their treatment journeys. As part of the PHYCOCARE® project, AlgoSource is conducting phase II clinical trials to validate product efficacy and scaling up production in an eco-friendly, semi-automated industrial facility.

Core Values
AlgoSource’s work is underpinned by three core principles:

• Natural origins: Products derived from local resources in Brittany and Loire-Atlantique, France.
• Scientific validation: Clinical studies demonstrating efficacy.

• Sustainability: Recognized as “exemplary” by Ethifinance in 2022 for its social and environmental commitment.

   

Investment in Innovation
Since its founding, AlgoSource has invested over €10 million in R&D. The company’s R&D team, composed of seven experts (as of September 2024), includes doctors, biochemical engineers, and technicians led by Scientific and Technical Director Olivier Lépine. Research focuses on three innovation pillars:

1. Identifying bioactive molecules.
2. Developing cultivation and extraction processes.

3. Validating product functionalities.

    

Company Structure and Leadership
AlgoSource employs 23 highly skilled individuals, with women comprising 50% of management roles. Structured as a Société Anonyme, the company is overseen by a board of directors, chaired by non-executive president Dominique Bouvier. Its executive team includes:

• Aymeric Loloum, CEO
• Olivier Lépine, Co-founder and Scientific Director
• Imma Gifuni, R&D Team Manager
• Matias Rodrigues, Industrial Performance Manager

The R&D process is guided by a Scientific and Innovation Committee established in 2020. This committee includes leading experts in microalgae and medical research, many of whom have ongoing collaborations or shareholder roles.

Collaborative Research
AlgoSource maintains a close partnership with the University of Nantes and CNRS through the GEPEA research lab and Algosolis platform, enabling advancements in biomass cultivation and extraction processes. These collaborations have led to multiple patents in industrial techniques and targeted prevention applications (e.g., NASH, oncology, cardiovascular health). AlgoSource has also participated in major research initiatives, including the H2020 MAGNIFICENT and PROFUTURE projects.

Clinical Applications
Another key collaborator is the Human Nutrition Research Center (CRNH-Ouest), led by Dr. K. Ouguerram. This partnership, active since 2010, has produced several scientific publications on the antioxidant properties of AlgoSource’s Spirulysat® product family, culminating in the highly concentrated PHYCOCARE® line.